Neoadjuvant Chemotherapy in Non-Small Cell Lung Cancer: A Standard Approach?

Albain K. , Rush V. , Crowley J. , Rice T. , Turrisi A. , Weick J. , Lonchyna V. , Presant C. , McKenna R. , Gandara D. , Fosmire H. , Taylor S. , Stelzer K. , Beasley K. , Livingstonm R. , for the Southwest Oncology Group Lung Committee: Long-term survival after concurrent cisplatin/etoposide (PE) plus chest radiotherapy (RT) followed by surgery in bulky, stages II-IA(N2) and IIIB non-small cell lung cancer (NSCLC): 6-year outcomes from Southwest Oncology Group Study 8805. Proc. ASCO: 1801, 1999.

Albain K.S. , Rusch V.W. , Crowley J.J. , Rice T.W. , Turrisi A.T. III , Weick J.K. , Lonchyna V.A. , Presant C.A. , McKenna R.J. , Gandara D.R. : Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA(N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J. Clin. Oncol., 13: 1880–1892, 1995.

Bains M.S. : Surgical treatment of lung cancer. Chest, 100: 826–837, 1991.

Betticher D.C. , Hsu Schmitz S.F. , Gauthier Y. , von Briel C. , Breitenbücher A. , Roth A. , Spiliopoulos A. , Pless M. , Stahel R. , Weder W. , Tötsch M. , Cerny T. , Ris H.B. : Neoadjuvant chemotherapy with docetaxel (DOC, taxotere) and cisplatin (cis) in patients (pts) with non-small cell lung cancer (NSCLC), stage IIIA,N2 is highly active with few toxicities. Proc. ASCO: 1824, 1999.

Burkes R.L. , Ginsberg R.J. , Shepherd F.A. , Blackstein M.E. , Goldberg M.E. , Walters P.F. , Patterson G.A. , Todd T. , Pearson F.G. , Cooper J.D. : Induction chemotherapy with mitomycin, vindesin, and cisplatin for stage III unresectable non-small-cell lung cancer: results of the Toronto phase II trial. J. Clin. Oncol., 10: 580–586, 1992.

Choi N.C. , Carey R.W. , Daly W. , Mathisen D. , Wain J. , Wright C. , Lynch T. , Grossbard M. , Grillo H. : Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small-cell lung cancer. J. Clin. Oncol., 15: 712–722, 1997.

Depierre A. , Milleron B. , Moro D. , Chevret S. , Braun D. , Quoix E. , Lebeau B. , Breton J.L. , Lemarié E. , Gouva S. , Paillot N. , Bréchot J.M. , Janicot H. , Lebas F.X. , Terrioux P. , Foucherr P. , Monchàtre M. , Coètmeur D. , Clavier J. , Villeneuve A. , Westeel V. , Chastang C. : Phase III trial of neo-adjuvant chemotherapy (NCT) in resectable stage I (except T1N0), II, IIIa non-small cell lung cancer: The French experience. Proc. ASCO: 1792, 1999.

Eberhardt W. , Wilke H. , Stamatis G. , Stuschke M. , Harstrick A. , Menker H. , Krause B. , Mueller M.R. , Stahl M. , Flasshove M. , Budach V. , Greschuchna D. , Konietzko N. , Sack H. , Seeber S. : Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definite surgery in locally advanced non-small-cell lung cancer: mature results of a phase II trial. J. Clin. Oncol., 16: 622–634, 1998.

Elias A.D. , Herndon J. , Kumar P. , Sugarbaker D. , Green M.R. : A phase III comparison of “best local-regional therapy'’ with or without chemotherapy for stage IIIA, T1-3N2. Proc. ASCO: 1611, 1997.

Fleck J. , Camargo J. , Godoy D. Chemoradiation therapy alone versus chemotherapy alone as a neoadjuvant treatment for stage III non-small cell lung cancer: Preliminary report of a phase III randomized trial. Proc ASCO: 1108, 1993.

Keller S. , Adak S. , Wagner H. , Herskovic A. , Brooks B.J. , Perry M.C. , Livingston R.B. , Johnson D.H. : Prospective randomized trial of postoperative adjuvant therapy in patients with completely resected stage II and IIIa non-small cell lung cancer: an intergroup trial (E3590). Proc. ASCO: 1793, 1999.

Martini N. , Flehinger B.J. : The role of surgery in N2 lung cancer. Surg. Clin. Nort. Am., 67: 1037–1049, 1987.

Martini N. , Kris M.G. , Flehinger B.J. , Gralla R.J. , Bains M.S. , Burt M.E. , Heelan R. , McCormack P.M. , Pisters K.M. , Rigas J.R. : Preoperative chemotherapy for stage IIIa (N2) lung cancer: the Sloan-Kettering experience with 136 patients. Ann. Thorac. Surg., 55: 1365–1374, 1993.

Monzó M. , Rosell R. , Sanchez J.J. , Lee S.S. , O'Brate A. , Gonzalez-Larriba J.L. , Alberola V. , Lorenzo J.C. , Nunez L. , Ro J.Y. , Martin C. : Paclitaxel resistance in non-small cell lung cancer associated with beta-tubulin gene mutations. J. Clin. Oncol., 6: 1786–1793, 1999.

Non-Small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individuals patients from 52 randomized clinical trials. BMJ, 899–909, 1995.

Pass H.I. , Pogrebniak H.W. , Steinberg S.M. , Mulshine J. , Minna J. : Randomized trial of neoadjuvant therapy for lung cancer: interim analysis. Ann. Thorac. Surg., 53: 992–998, 1992.

Pisters K.M. , Ginsberg R.J. , Giraux D.J. , Putnam J.B. , Kris M.G. , Johnson D.H. , Roberts J.R. , Mault J. , Crowley J.J. , Bunn P.A. Jr. : Induction chemotherapy before surgery for early-stage lung cancer: a novel approach. Bimodality Lung Oncology Team. J. Thorac. Cardiovasc. Surg., 1199: 429–439, 2000.

Rosell R. : The integration of newer agents into neoadjuvant therapy. Semin. Oncol., 25: S24–S27, 1998.

Rosell R. , Carrato A. : From the bench to the bed: the need for translational research. Revista de Oncologia, 4: 181–187, 1999.

Rosell R. , Felip E. : Role of multimodality treatment for lung cancer. Semin. Surg. Oncol., 18: 143–151, 2000.

Rosell R. , Font A. , Pifarré A. , Canela M. , Maurel J. , Arellano A. , Izquierdo J. : The role of induction (neoadjuvant) chemotherapy in stage IIIA non-small-cell lung cancer. Chest, 109: S102–S106, 1996.

Rosell R. , Gómez-Codina J. , Camps C. , Maestre J. , Padille J. , Canto A. , Mate J.L. , Li S. , Roig J. , Olazabal A. : A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N. Engl. J. Med., 330: 153–158, 1994.

Rosell R. , Gómez-Codina J. , Camps C. , Sanchez J.J. , Maestre J. , Padilla J. , Canto A. , Abad A. , Roig J. : Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: definitive analysis of a randomized controlled trial. Lung Cancer, 26: 7–14, 1999.

Rosell R. , López-Cabrerizo M.P. , Astudillo J. : Preoperative chemotherapy for stage IIIA non-small cell lung cancer. Curr. Opin. Oncol., 9: 149–155, 1997.

Rosell R. , Monzó M. , Sánchez J.M. , O'Brate A. , Nogales E. , Guillot M. , Sánchez J.J. , Aracil C. : Beta-tubulin mutations in circulating extracellular DNA of non-small-cell lung cancer (NSCLC) patients (pts). Proc. ASCO: 1897, 2000.

Roth J.A. , Atkinson E.N. , Fossella F. , Komaki R. , Ryan M.B. , Putnam J.B. , Lee J.S. , Dhingra H. , De Caro L. , Chasen M. , Hong W.K. : Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. Lung Cancer, 21: 1–6, 1998.

Roth J.A. , Fossella F. , Komaki R. , Ryan M.B. , Putnam J.B. , Lee J.S. , Dhingra H. , De Caro L. , Chasen M. , McGavran M. : A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small cell lung cancer. J. Natl. Cancer Inst., 86: 673–680, 1994.

Shepherd F.A. , Johnston M.R. , Payne D. , Burkes R. , Deslauriers J. , Cormier Y. , de Bedoya L.D. , Ottaway J. , James K. , Zee B. : Randomized study of chemotherapy and surgery versus radiotherapy for stage IIIA non-small-cell lung cancer: a National Cancer Institute of Canada Clinical Trials Group study. Br. J. Cancer, 78: 683–685, 1998.

Sugarbaker D.J. , Herndon J. , Kohman L.J. , Krasna M.J. , Green M.R. : Results of Cancer and Leukemia Group B Protocol 8935: a multiinstitutional phase II trimodality trail for stage IIIA(N2) non-small-cell lung cancer. J. Thorac. Cardiovasc. Surg., 109: 473–485, 1995.

Thomas M. , Rube C. , Semik M. , von Eiffm , Frestag L. , Macha N.H. , Wagner W. , Klinke F. , Scheld H.H. , Willich N. , Berdel W.E. , Junker K. : Impact of preoperative bimodality induction including twice-daily radiation on tumor regression and survival in stage III non-small-cell lung cancer. J. Clin. Oncol., 17: 1185–1193, 1999.

Van Zandwijk N. , Crino L. , Kramer G.W. , Gans S. , Schramel EM. , Termeer A. , Schlösser N.J. , Postmus P.E. , Daamen S. , van Glabbeke M. , Giaccone G. the EORTC LCCG: Phase II study of gemcitabine plus cisplatin as induction regimen for patients with stage IIIA non-small cell lung cancer by the EORTC lung cancer cooperative group (EORTC 08955). Proc. ASCO: 1799, 1998.